Skip to main content

Advertisement

SpringerLink
Log in

Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy

  • Lymphomas (MR Smith, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of the study is to summarize the current conundrums in the management of marginal zone lymphomas (MZL).

Recent Findings

In 2017, the US Food and Drug Administration (FDA) approved ibrutinib, a first in class Bruton Tyrosine Kinase inhibitor, for the treatment of relapsed/refractory MZL based on pivotal open-label phase II trial demonstrating an overall response rates of 48%. Clinical trials design utilizing chemotherapy-free regimens for relapsed/refractory disease are gaining popularity. Recent studies have identified multiple genetic biomarkers that helped characterize and prognosticate different subtypes of MZL.

Summary

MZLs are heterogeneous, mostly indolent, malignancies derived from B lymphocytes. Three disease subtypes are recognized, extranodal, nodal, and splenic. The disease characteristics, clinical picture, and treatment algorithms vary considerably based on subtype and site of involvement. Recent discoveries have enhanced our knowledge of the pathogenesis of MZLs leading to development of more accurate prognostic models as well as novel targeted systemic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma. Blood 1997; 89(11):3909–18.

  2. Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma. 2013;54(7):1380–6. https://doi.org/10.3109/10428194.2012.743655.

    Article  PubMed  Google Scholar 

  3. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95(6):1950–6.

    CAS  PubMed  Google Scholar 

  4. Chacon JI, Mollejo M, Munoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648–54.

    CAS  PubMed  Google Scholar 

  5. • Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643–9. https://doi.org/10.1182/blood-2005-11-4659. One of the earliest models for prognostication of SMZL by The Integruppo Italiano Linfomi (IIL) based on a large case series of 309 patients.

    Article  CAS  PubMed  Google Scholar 

  6. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-cell lymphoma group. Blood. 2010;116(9):1479–88. https://doi.org/10.1182/blood-2010-02-267476.

    Article  CAS  PubMed  Google Scholar 

  7. Swerdlow SH, Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W. WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. IARC. 2008.

  8. • Parry M, Rose-Zerilli MJJ, Ljungström V, Gibson J, Wang J, Walewska R, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174. Recent study describing genetic changes that help prognosticate SMZL–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. • Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553–65. https://doi.org/10.1084/jem.20120910. Recent study describing genetic changes that help prognosticate SMZL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. • Piva R, Deaglio S, Fama R, Buonincontri R, Scarfo I, Bruscaggin A, et al. The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29(2):503–7. https://doi.org/10.1038/leu.2014.294. Recent study describing genetic changes that help prognosticate SMZL.

    Article  CAS  PubMed  Google Scholar 

  11. • Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29(5):1177–85. https://doi.org/10.1038/leu.2014.330. Recent study describing genetic changes that help prognosticate SMZL.

    Article  CAS  PubMed  Google Scholar 

  12. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537–51. https://doi.org/10.1084/jem.20120904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene <em>API2</em> and a novel 18q gene,<em>MLT,</em> are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93(11):3601–9.

    CAS  PubMed  Google Scholar 

  14. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19(4):652–8. https://doi.org/10.1038/sj.leu.2403644.

    Article  CAS  PubMed  Google Scholar 

  15. • Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128(10):1362–73. https://doi.org/10.1182/blood-2016-02-696757. Recent report of genetic changes unique to NMZL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, et al. Whole-genome sequencing identifies recurrent somatic <em>NOTCH2</em> mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martinez N, Almaraz C, Vaque JP, Varela I, Derdak S, Beltran S, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28(6):1334–40. https://doi.org/10.1038/leu.2013.365.

    Article  CAS  PubMed  Google Scholar 

  18. Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. https://doi.org/10.1371/journal.pone.0083244.

    Article  PubMed  PubMed Central  Google Scholar 

  19. • Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930–4. https://doi.org/10.1182/blood-2011-06-359166. Alteration of NF-kB pathway in SMZL.

    Article  PubMed  Google Scholar 

  20. Martinez-Lopez A, Curiel-Olmo S, Mollejo M, Cereceda L, Martinez N, Montes-Moreno S, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol. 2015;39(5):644–51. https://doi.org/10.1097/pas.0000000000000411.

    Article  PubMed  Google Scholar 

  21. Peveling-Oberhag J, Wolters F, Doring C, Walter D, Sellmann L, Scholtysik R, et al. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. BMC Cancer. 2015;15:773. https://doi.org/10.1186/s12885-015-1766-z.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96(1):35–45.

    Article  CAS  PubMed  Google Scholar 

  23. • Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101(6):2335–9. https://doi.org/10.1182/blood-2002-09-2963.

    Article  CAS  PubMed  Google Scholar 

  24. Algara P, Mateo MS, Sanchez-Beato M, Mollejo M, Navas IC, Romero L, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99(4):1299–304.

    Article  CAS  PubMed  Google Scholar 

  25. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072–81.

    Article  CAS  PubMed  Google Scholar 

  26. •• Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94. https://doi.org/10.1056/NEJMoa013376. Initial report documeting regression of SMZL after HCV therapy.

    Article  CAS  PubMed  Google Scholar 

  27. Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol. 1996;93(3):731–6.

    Article  CAS  PubMed  Google Scholar 

  28. Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernandez JM, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25(10):1268–76.

    Article  CAS  PubMed  Google Scholar 

  29. •• Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159(2):164–71. https://doi.org/10.1111/bjh.12011. HPLL prognostic scheme report of the international collaboration of SMZLSG of 593 patients. The largest case series published to date.

    Article  PubMed  Google Scholar 

  30. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, et al. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Hematology. 2017;22(7):405–11. https://doi.org/10.1080/10245332.2017.1279842.

    Article  PubMed  Google Scholar 

  31. Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the follicular lymphoma international prognostic index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer. 2013;119(1):99–106. https://doi.org/10.1002/cncr.27704.

    Article  PubMed  Google Scholar 

  32. •• Rosado MF, Byrne GE Jr, Ding F, Fields KA, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006;107(2):467–72. https://doi.org/10.1182/blood-2005-06-2332. One of the largest cohorts of ocular adnexal MZL showing associatin with C. psittaci

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102(5):1628–38.

    Article  CAS  PubMed  Google Scholar 

  34. Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, Ota H. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter. 2006;11(2):86–95. https://doi.org/10.1111/j.1523-5378.2006.00382.x.

    Article  PubMed  Google Scholar 

  35. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457–61.

    Article  CAS  PubMed  Google Scholar 

  36. Chanudet E, Zhou Y, Bacon CM, Wotherspoon AC, Muller-Hermelink HK, Adam P, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344–51. https://doi.org/10.1002/path.1984.

    Article  CAS  PubMed  Google Scholar 

  37. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51–60. https://doi.org/10.1093/jnci/djj004.

    Article  PubMed  Google Scholar 

  38. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113(3):321–33. https://doi.org/10.1172/JCI20925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M, et al. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis. 2003;187(2):334–7. https://doi.org/10.1086/367807.

    Article  CAS  PubMed  Google Scholar 

  40. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8(2):105–10. https://doi.org/10.1016/j.cgh.2009.07.017.

    Article  PubMed  Google Scholar 

  41. • Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507–13. https://doi.org/10.1136/gutjnl-2011-300495. Large cohort from Japan showing excellent outcomes of gastric MALT after H. pylori eradication.

    Article  PubMed  Google Scholar 

  42. Murga Penas EM, Hinz K, Roser K, Copie-Bergman C, Wlodarska I, Marynen P, et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia. 2003;17(11):2225–9. https://doi.org/10.1038/sj.leu.2403122.

    Article  CAS  PubMed  Google Scholar 

  43. Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood. 2005;105(7):2891–9. https://doi.org/10.1182/blood-2004-06-2297.

    Article  CAS  PubMed  Google Scholar 

  44. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science. 2011;331(6016):468–72. https://doi.org/10.1126/science.1198946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. • Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101(7):2547–50. https://doi.org/10.1182/blood-2002-10-3167. Initial report of t(11;18) associating H. pylori - negative gastric MALT.

    Article  CAS  PubMed  Google Scholar 

  46. •• Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357(9249):39–40. https://doi.org/10.1016/s0140-6736(00)03571-6. Initial report of t(11;18) as a marker of resistance of gastric MALT to H. pylori eradication.

    Article  CAS  PubMed  Google Scholar 

  47. • Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490–7. https://doi.org/10.1200/jco.2006.05.6150. Initial report of Forkhead box protein P1 as marker of poor outcomes in EMZL.

    Article  CAS  PubMed  Google Scholar 

  48. • Teckie S, Qi S, Lovie S, Navarrett S, Hsu M, Noy A, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130–7. https://doi.org/10.1016/j.ijrobp.2015.01.040. Long term follow up report of excellent long term outcomes after radiation in early stage EMZL.

    Article  PubMed  Google Scholar 

  49. • Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409. MALT lymphoma prognostic index.

    Article  PubMed  Google Scholar 

  50. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, et al. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. Br J Haematol. 2016;173(3):404–12. https://doi.org/10.1111/bjh.13975.

    Article  CAS  PubMed  Google Scholar 

  51. Camacho FI, Algara P, Mollejo M, Garcia JF, Montalban C, Martinez N, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol. 2003;27(6):762–71.

    Article  PubMed  Google Scholar 

  52. Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, et al. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. Br J Haematol. 2016;175(2):275–80. https://doi.org/10.1111/bjh.14228.

    Article  CAS  PubMed  Google Scholar 

  53. Traverse-Glehen A, Davi F, Ben Simon E, Callet-Bauchu E, Felman P, Baseggio L, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica. 2005;90(4):470–8.

    CAS  PubMed  Google Scholar 

  54. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol. 2001;159(1):253–61. https://doi.org/10.1016/s0002-9440(10)61691-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hart GT, Wang X, Hogquist KA, Jameson SC. Kruppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A. 2011;108(2):716–21. https://doi.org/10.1073/pnas.1013168108.

    Article  CAS  PubMed  Google Scholar 

  56. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol. 2009;9(11):767–77. https://doi.org/10.1038/nri2656.

    Article  CAS  PubMed  Google Scholar 

  57. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol. 2006;85(11):781–6. https://doi.org/10.1007/s00277-006-0160-y.

    Article  PubMed  Google Scholar 

  58. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007;136(2):301–4. https://doi.org/10.1111/j.1365-2141.2006.06437.x.

    Article  PubMed  Google Scholar 

  59. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31. https://doi.org/10.1016/j.ijrobp.2015.01.009.

    Article  PubMed  Google Scholar 

  60. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82. https://doi.org/10.1093/jnci/djj373.

    Article  CAS  PubMed  Google Scholar 

  61. •• Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988–94. https://doi.org/10.1200/jco.2011.41.4466. International phase II trial documenting remission of ocular adnexae lymphoma after C. psittaci eradication with doxycycline.

    Article  CAS  PubMed  Google Scholar 

  62. •• Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23(31):8018–24. https://doi.org/10.1200/jco.2005.02.3903. One of the largest long-term follow up reports from Europe (median follow up 6 years) showing excellent outcomes after H. pylori eradication and documenting t(11;18) as a maker of resistance to eradication.

    Article  PubMed  Google Scholar 

  63. • Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342(8871):575–7. Initial report of regression of gastric MALT after H. pylori eradication in 6 patients.

    Article  CAS  PubMed  Google Scholar 

  64. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol. 2005;23(1):10–7. https://doi.org/10.1002/hon.743.

    Article  PubMed  Google Scholar 

  65. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78(2):206–9.

    Article  CAS  PubMed  Google Scholar 

  66. • Lenglet J, Traulle C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2014;55(8):1854–60. https://doi.org/10.3109/10428194.2013.861067. One of the largest case series and longest follow-up for splenectomy of SMZL.

    Article  PubMed  Google Scholar 

  67. Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012;87(11):E119–E22. https://doi.org/10.1002/ajh.23314.

    Article  PubMed  Google Scholar 

  68. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107(1):125–35. https://doi.org/10.1002/cncr.21931.

    Article  CAS  PubMed  Google Scholar 

  69. Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18(2):190–7. https://doi.org/10.1634/theoncologist.2012-0251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90(6):856–8.

    CAS  PubMed  Google Scholar 

  71. Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322–8. https://doi.org/10.1111/bjh.12036.

    Article  CAS  PubMed  Google Scholar 

  72. Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25(3):127–31. https://doi.org/10.1002/hon.820.

    Article  CAS  PubMed  Google Scholar 

  73. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404–10. https://doi.org/10.1093/annonc/mdu166.

    Article  CAS  PubMed  Google Scholar 

  74. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(6):452–7. https://doi.org/10.3816/CLML.2010.n.079.

    Article  CAS  PubMed  Google Scholar 

  75. •• Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. https://doi.org/10.1016/S0140-6736(12)61763-2. Landmark randomized phase III trial of the German Study group indolent Lymphomas (StiL) showing superiority of BR over R-CHOP as frontline treatment of indolent lymphoma.

    Article  CAS  PubMed  Google Scholar 

  76. •• Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52. https://doi.org/10.1182/blood-2013-11-531327. International phase III trial showing very similar results to the StiL trial (ref. 65 above) based on StiL and BRIGHT data, BR became the preferred upfront agent in indolent lymphomas.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, et al. Long-term results of the multicenter phase ii trial with BENDAMUSTINE and rituximab as FIRST line treatment for patients with malt lymphoma (MALT-2008-01). Hematol Oncol. 2017;35:147–8. https://doi.org/10.1002/hon.2437_137.

    Article  Google Scholar 

  78. Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2012;91(4):543–51. https://doi.org/10.1007/s00277-011-1337-6.

    Article  CAS  PubMed  Google Scholar 

  79. Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741–8. https://doi.org/10.1111/j.1365-2141.2009.07677.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer. 2012;118(16):3954–61. https://doi.org/10.1002/cncr.26708.

    Article  CAS  PubMed  Google Scholar 

  81. • Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol. 2017;35(17):1905–12. https://doi.org/10.1200/jco.2016.70.6994. Randomized trial showing superiority of chlorambucil in combination with rituximab over either alone in MALT lymphoma failing local or H. pylori eradication therapy.

    Article  PubMed  Google Scholar 

  82. • Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. The Lancet Oncology. 17(8):1081–93. https://doi.org/10.1016/S1470-2045(16)30097-3. Recent trial showing addition of obinutuzumab to bendamustine is superior to bendamustine alone in patients with idolent lymphomas who are rituximab refractory.

  83. •• Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–32. https://doi.org/10.1182/blood-2016-10-747345. Recent landmark phase II trial showing single-agent ibrutinib induced durable remissions with a favorable benefit-risk profile in patients with previously treated MZL. Trial led to FDA approval of ibrutinib to be the first agent in history specifically approved by the FDA for MZL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the international extranodal lymphoma study group (IELSG). Ann Oncol. 2011;22(3):689–95. https://doi.org/10.1093/annonc/mdq416.

    Article  CAS  PubMed  Google Scholar 

  85. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023–30. https://doi.org/10.1200/JCO.2008.17.7980.

    Article  PubMed  Google Scholar 

  86. • Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, et al. A phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Blood. 2016; https://doi.org/10.1182/blood-2016-06-720599. Recent trial confirming activity of lenalidomide with rituximab in MALT lymphoma.

  87. • Andorsky DJ, Yacoub A, Bitran JD, Melear J, Brooks HD, Foon KA, et al. MAGNIFY: phase iiib randomized study of lenalidomide plus rituximab (R<sup>2</sup>) followed by lenalidomide vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone, or mantle cell lymphoma. Blood. 2016;128(22):1798. Recent trial confirming activity of lenalidomide with rituximab in indolent lymphomas.

    Google Scholar 

  88. Gerecitano JF, Roberts AW, Seymour JF, Wierda WG, Kahl BS, Pagel JM, et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254.

    Google Scholar 

  89. Dreyling M, Cunningham D, Bouabdallah K, Assouline S, Van den Neste E, Vitolo U, et al. Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma. Blood. 2014;124(21):1701.

    Google Scholar 

  90. Maddocks KJ, Cohen JB, Huang Y, Christian BA, Benson DM, Jones J et al. A phase I study of BKM120 (Buparlisib) and rituximab in patients with relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL). Blood 2016;128(22):1776.

  91. Zinzani P, Wagner-Johnston N, Miller C, Ardeshna K, Tertreault S, Assouline S, et al. DYNAMO: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double-refractory indolent non-Hodgkin lymphoma. Hematol Oncol. 2017;35:69–70. https://doi.org/10.1002/hon.2437_57.

    Article  Google Scholar 

  92. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18. https://doi.org/10.1056/NEJMoa1314583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Kiesewetter B, Troch M, Dolak W, Mullauer L, Lukas J, Zielinski CC, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013;98(3):353–6. https://doi.org/10.3324/haematol.2012.065995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–8. https://doi.org/10.1016/s1470-2045(14)70455-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the international extranodal lymphoma study group (IELSG). Ann Oncol. 2011;22(3):689–95. https://doi.org/10.1093/annonc/mdq416.

    Article  CAS  PubMed  Google Scholar 

  96. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, et al. Phase II study of Vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198–203. https://doi.org/10.1200/JCO.2010.32.1398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, et al. Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised gallium trial with previously untreated marginal zone lymphoma (MZL). Hematol Oncol. 2017;35:146–7. https://doi.org/10.1002/hon.2437_136.

    Article  Google Scholar 

  98. • Nastoupil L, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, et al. Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL. Hematol Oncol. 2017;35:112–3. https://doi.org/10.1002/hon.2437_101. Very recent chemotherapy-free triplet regimen for indolent lymphoma.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), 320 W. 10th Avenue, A352, Columbus, OH, 43210, USA

    Sabarish Ayyappan & Basem M. William

Authors
  1. Sabarish Ayyappan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basem M. William
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basem M. William.

Ethics declarations

Conflict of Interest

Sabarish Ayyappan and Basem M. William declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayyappan, S., William, B.M. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. Curr Oncol Rep 20, 33 (2018). https://doi.org/10.1007/s11912-018-0687-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-018-0687-9

Keywords

Search

Navigation